Buy Orforglipron in New York | ≥99% Purity | QSC Peptides
Buy Orforglipron in New York
QSC research-grade Orforglipron — oral non-peptide GLP-1R agonist — ships domestically to New York from the US Domestic Warehouse. ≥99% purity · HPLC + MS verified · Janoshik COA · Free shipping.
≥99% Purity 2–5 business days Janoshik COA Free Shipping
Why Researchers in New York Order Orforglipron from QSC
Orforglipron (LY3502970) is Eli Lilly’s oral non-peptide GLP-1 receptor agonist — the first small molecule GLP-1R agonist to complete Phase 3 trials and receive FDA approval (2025). For researchers in New York, QSC provides the most direct supply route: domestic fulfillment from the US Domestic Warehouse means no customs risk, local courier tracking, and delivery in 2–5 business days.
QSC is the direct SPPS manufacturer, not a reseller. Every Orforglipron batch is verified at ≥99% purity by HPLC and mass spectrometry with a Janoshik-independent COA published on the product page — the same independent verification standard used by the broader research community.
Shipping Details — New York
Warehouse
US Domestic Warehouse
Delivery Time
2–5 business days
Customs
Ships from US warehouse — no import fees or customs required
Tracking
Provided within 12–48 hours of dispatch
Payment
Bitcoin (BTC) · USDT ERC-20
About Orforglipron — Research Background
Orforglipron is the first oral, non-peptide GLP-1 receptor agonist to reach advanced clinical development. Unlike peptide-based GLP-1R agonists (semaglutide, liraglutide, tirzepatide), orforglipron binds an allosteric transmembrane site on GLP-1R — enabling reliable oral bioavailability without the fasting requirements of oral semaglutide (Rybelsus).
Phase 2 trials published in NEJM (2023) documented 8–15% mean body weight reduction and HbA1c reductions of 1.4–2.1% over 26 weeks. The Phase 3 ATTAIN program confirmed efficacy and safety; ATTAIN-CVOT demonstrated statistically significant cardiovascular risk reduction. Orforglipron received FDA approval for type 2 diabetes in 2025.
For researchers in New York, orforglipron offers a unique tool for studying selective oral GLP-1R agonism, allosteric receptor pharmacology, and oral vs injectable GLP-1R agonist comparisons in metabolic research models. See the full Orforglipron Research Hub for mechanism, protocols, and published studies.
QSC Orforglipron — Quality Specifications
Purity
≥99% by HPLC (peak area method)
Identity
Mass spectrometry — MW 517.5 g/mol confirmed
COA
Janoshik-verified · Published on product page
Form
Lyophilized powder · Store at -20°C
Frequently Asked Questions
Is it legal to buy Orforglipron for research in New York?
Orforglipron is sold by QSC strictly for laboratory research purposes. Researchers in New York are responsible for understanding and complying with applicable local regulations. QSC makes no representations regarding regulatory status beyond the research-use-only designation.
How is Orforglipron different from Semaglutide?
Semaglutide is a peptide GLP-1R agonist administered by weekly subcutaneous injection. Orforglipron is a non-peptide small molecule taken once daily as an oral tablet with no fasting requirements — activating the same GLP-1 receptor via a different allosteric binding site. This distinction makes orforglipron uniquely valuable for oral GLP-1R agonism research and compliance studies.
What purity is QSC Orforglipron?
≥99% by HPLC and mass spectrometry. COA published on product page, independently verifiable via verify.janoshik.com.
Research Use Only: All products sold on qsc-eu.com are intended strictly for laboratory research purposes only. They are not approved for human consumption, veterinary use, or any other application. Researchers are responsible for understanding and complying with local regulations in their jurisdiction.
